DAY 4 - Tuesday, October 25
|
|
OCULOPLASTICS
Treat eyelid necrosis rapidly
Orlando—Brown recluse spider bites can be deadly; however, the victims of most bites do not develop necrosis if treated rapidly. Ralph Wesley, MD, discussed ocular spider bites and their management during the presentation of the Wendell L. Hughes Lecture. » MORE
|
|
GLAUCOMA
Adherence, outcome linked
Orlando—The adherence of patients with glaucoma with their follow-up appointments prior to trabeculectomy is an independent risk factor for trabeculectomy outcome, said Ian A. Rodrigues, MD. » MORE
|
|
CORNEA
Study: Long-term CXL
Orlando—Results from a study with 4 years of follow-up provide confirmation of refractive stability and halting of disease progression in eyes with keratoconus treated by corneal collagen crosslinking (CXL), said Dilraj Grewal, MD. » MORE |
|
REFRACTIVE
CXL, TG-PRK favorable
Orlando—Analyses of early outcome data from a small patient population show that simultaneous corneal collagen crosslinking (CXL) with topography-guided photorefractive keratectomy (TG-PRK) using a proprietary 1 kHz excimer laser system (iVIS) with a new algorithm is a promising treatment for eyes with contact lens-intolerant keratoconus, said David Lin, MD. » MORE
|
|
NEURO-OPHTHALMOLOGY
Look for obvious in diplopia
Orlando—Screening for the obvious factors can identify oblique diplopia during examination. Brian Younge, MD, described the best methods to ensure a correct diagnosis. » MORE
|
|
Intermittent diplopia challenging
Orlando—Intermittent diplopia often is not evident during presentation. The history-taking is a challenge because it is unknown if the diplopia is indeed intermittent or intermittently noticed, induced with activity, or worsened with fatigue. Kathleen Digre, MD, described how to ferret out this diagnosis. » MORE
|
|
RETINA
Review: VIEW studies
Orlando—Results from an integrated analysis of data from 12 months of follow-up in the two similarly designed prospective, randomized studies comparing VEGF Trap-Eye (VTE) (aflibercept; Eylea, Regeneron/Bayer) and ranibizumab (Lucentis, Genentech) indicate that intravitreal injection of VTE every 2 months is predictably effective therapy for neovascular age-related macular degeneration (AMD) and comparable to monthly ranibizumab 0.5 mg, said Ursula M. Schmidt-Erfurth, MD. » MORE |
|
Protein effective for DME
Orlando—Treatment with a fusion protein resulted in a significant increase in visual acuity and a significant decrease in retinal thickness at months 6 and 12 in patients with diabetic macular edema (DME), said Diana Do, MD. » MORE |
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
|
|
Exhibit Hall Hours
Saturday, October 22
9 a.m. – 5 p.m.
Sunday, October 23
9 a.m. – 5 p.m.
Monday, October 24
9 a.m. – 5 p.m.
Tuesday, October 25
9 a.m. – 3 p.m.
We welcome your feedback!
Please send your comments to:
Mark Dlugoss
Editor-in-Chief
Advanstar Eye Health Group
mdlugoss@advanstar.com |
|
